| 46.95 -0.35 (-0.74%) | 04-14 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 55.9 |
1-year : | 58.43 |
| Resists | First : | 47.86 |
Second : | 50.02 |
| Pivot price | 47.22  |
|||
| Supports | First : | 44.36 |
Second : | 36.9 |
| MAs | MA(5) : | 47.14 |
MA(20) : | 46.91 |
| MA(100) : | 43.83 |
MA(250) : | 36.61 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 48.3 |
D(3) : | 49.2 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 50.02 | Low : | 19.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KNSA ] has closed above bottom band by 45.4%. Bollinger Bands are 11.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 48.5 - 48.84 | 48.84 - 49.1 |
| Low: | 45.97 - 46.33 | 46.33 - 46.61 |
| Close: | 46.84 - 47.39 | 47.39 - 47.81 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Mon, 13 Apr 2026
Insider Sell: Michael Megna Sells Shares of Kiniksa Pharmaceuticals International PLC - GuruFocus
Mon, 13 Apr 2026
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells 6,625 Shares of Stock - MarketBeat
Mon, 13 Apr 2026
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Ross Moat Sells 1,703 Shares - MarketBeat
Sun, 12 Apr 2026
If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA) - Stock Titan
Sat, 11 Apr 2026
A Look At Kiniksa Pharmaceuticals (KNSA) Valuation As Heart’s Home Campaign Targets ARCALYST Growth - simplywall.st
Fri, 10 Apr 2026
The Technical Signals Behind (KNSA) That Institutions Follow - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 103.4 (%) |
| Shares Short | 3,770 (K) |
| Shares Short P.Month | 3,060 (K) |
| EPS | 0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.44 |
| Profit Margin | 8.7 % |
| Operating Margin | 9.7 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 11.7 % |
| Qtrly Rev. Growth | 65 % |
| Gross Profit (p.s.) | 8.06 |
| Sales Per Share | 14.76 |
| EBITDA (p.s.) | 1.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 138 (M) |
| Levered Free Cash Flow | 98 (M) |
| PE Ratio | 62.64 |
| PEG Ratio | 0 |
| Price to Book value | 6.31 |
| Price to Sales | 3.18 |
| Price to Cash Flow | 15.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|